Infusion Pump Market to Surpass US$ 16.91 Bn by 2030 - Coherent Market Insights

An infusion pump is a medical device used to deliver fluids into the patient's body in a controlled manner. Infusion pumps are capable of delivering fluids in small or large amounts, and are used to deliver medications or nutrients, such as insulin or other hormones, pain relievers, antibiotics, and chemotherapy drugs, among others. Some infusion pumps are designed mainly for stationary use, while others are designed to be portable or wearable. Different types of infusion pumps are used for different purposes and in a variety of environments.

Market Statistics:

The Global Infusion Pump Market is estimated to account for US$ 9.62 Bn in terms of value by the end of 2023.

Drivers:

Increasing demand for smart, technologically advanced infusion pumps worldwide is expected to augment the growth of the global infusion pump market during the forecast period. For instance, with the rise in burden of chronic disease and growing geriatric population, the use or demand for smart, technologically advanced infusion pumps is also increasing. In March 2022, Fresenius Kabi acquired the smart infusion pump maker, Ivenix, to bolster its intravenous drug offerings. Ivenix’s infusion pump includes a digital, large-volume pump plus accompanying administration hardware as well as software and analytics tools designed to help reduce medical errors. Moreover, in August 2018, Baxter received clearance to market its smart infusion pump in Australia, New Zealand, and the European Union. This in turn is driving the market growth.

Opportunities:

Rise in burden of chronic disease and growing geriatric population across the globe is expected to offer significant growth opportunities for the global infusion pump market. For instance, infusion pump delivers fluids into a patient's body in controlled amounts, and replaces the need for multiple injections with a continuous insulin infusion and helps improve blood sugar levels. According to the International Diabetes Federation (IDF), around 537 million adults (20 to 79 years) are living with diabetes, and the number of people living with diabetes is expected to reach 643 million by 2030 and 783 million by 2045. Diabetes is common in the elderly population, and thus, with the rise in burden of diabetes, the demand for insulin pump is also increasing rapidly.

Restraints:

Safety issues and stringent regulations and high cost of infusion pumps are major factors expected to hamper growth of the global infusion pump market. Infusion pumps pose risks to patient safety due to their complexity and multiple steps required in their administration. Studies have found that IV infusion is associated with around 56% of medication errors, 54% of all adverse drug events, and 61% of serious and life-threatening errors. Therefore, the quality of device and their approvals are governed by the regulatory authorities to protect the risks associated with design, manufacture, and packaging of the device. Moreover, the cost of infusion pump is directly associated to the type, specification, and features of the infusion pump, and it also depends of the brand or company.

- Impact of Coronavirus (Covid-19) Pandemic

The outbreak of COVID-19 had a positive impact on the infusion pump market. In April 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of B. Braun's Perfusor Space Syringe Infusion Pump, Infusomat Space Volumetric Infusion Pump, and Outlook ES Pump systems for use in tracheal delivery of continuous nebulized medications into nebulizer to treat patients of all ages with or suspected of having COVID-19 and to decrease the exposure of healthcare providers (HCP) to such patients during the COVID-19 pandemic. This authorization allows for an alternative method to administer continuous nebulized medications to patients who are critically ill with COVID-19, many of whom are on ventilation,

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/infusion-pumps-market-127

Key Takeaways:

The global infusion pump market was valued at US$ 8.87 Bn in 2022 and is forecast to reach a value of US$ 16.91 Bn by 2030 at a CAGR of 8.4% between 2023 and 2030.

Large volume infusion pump segment held dominant position in the global infusion pump market in 2022, accounting for 27.2% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends:

Increasing number of surgical procedures is one of the key trends expected to boost the growth of the global infusion pump market. Infusion pumps play a key role in drug administration in surgical patients; are of significant concern to anesthesiologists. Infusion pump, such as elastomeric pumps, are used to administer liquid drugs such as local anesthetics, analgesics, cytostatics, or antibiotics (depending on the therapy). They are designed for continuous drug delivery, on-demand delivery, or combination of both continuous and on-demand drug delivery. Thus, with the increasing number of surgical procedures, the use or demand for infusion pumps is also increasing rapidly. This trend is expected to continue during the forecast period.

Competitive Landscape:

Major players operating in the global infusion pump market include BD, Fresenius Kabi, ICU Medical, Smiths Medical, Medtronic, and B. Braun Melsungen, among others.

Recent Developments:

In September 2022, Insulet announced that the Omnipod 5 system received CE mark clearance, making it available throughout the European Union. It’s cleared for use by adults and children aged two and older with type-1 diabetes.

In August 2022, Baxter International Inc. received the U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) built to help reduce infusion errors and designed to meet rigorous FDA guidance for infusion devices.